{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:21:02Z","timestamp":1785522062322,"version":"3.56.0"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"16","funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["18185"],"award-info":[{"award-number":["18185"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Nephropathy diabetes is one of the important causes of death and a more prevalent\ncause of end-stage renal disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The present study investigated the effect of applying spironolactone and captopril and their combination\non some renal performance indices and cholesterol-efflux-related gene expression in nephropathy diabetic\nrats.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Intraperitoneal injection of streptozotocin was used to induce diabetes in rats. FBS, creatinine, and\nBUN were assayed using the calorimetry technique; also, urine microalbumin was assayed by ELISA. Hepatic\ngene expressions of ABCA1, ABCG1, and miR-33 were evaluated by the real-time PCR method.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>FBS levels in the captopril-treated group were significantly decreased compared with the untreated diabetic\ngroup. BUN levels of treated groups with captopril and a combination of captopril + spironolactone were\nsignificantly increased. GFR of both treated diabetic groups with captopril and spironolactone was significantly\nlower than an untreated diabetic group. ABCA1 gene expression in hepatic cells of the combination of spironolactone\n+ captopril treated group was significantly increased compared to other treated and untreated diabetic\ngroups. The hepatic expression of the ABCG1 gene in the treated and untreated diabetic groups was significantly\nlower than in the control group. Treatment of the diabetic group with only combination therapy decreased the\nhepatic gene expression of miR-33 significantly.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Obtained results suggest that S+C combination therapy can improve nephropathy and diabetes\ndisorders by targeting the ABCA1 and miR-33 gene expression. It is suggested that miR-33 and ABCA1 genes\nevaluation could be a new therapeutic strategy for nephropathy diabetes remediation.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612828666220401143249","type":"journal-article","created":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T18:09:36Z","timestamp":1649009376000},"page":"1367-1372","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Captopril and Spironolactone can Attenuate Diabetic Nephropathy in Wistar Rats\nby Targeting ABCA1 and microRNA-33"],"prefix":"10.2174","volume":"28","author":[{"given":"Tina","family":"Ghaffari","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariman","family":"Moradi","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry,\nSchool of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Chamani","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry,\nFaculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Ebadi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Fadaei","sequence":"additional","affiliation":[{"name":"Sleep Disorders Research Center, Research Institute\nfor Health, Kermanshah University of Medical Sciences, Kermanshah, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Alizadeh-Fanalou","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran"},{"name":"Nephrology and Kidney Transplant Research Center,\nClinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Yarahmadi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soudabeh","family":"Fallah","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"450639","DOI":"10.1155\/2013\/450639","volume":"2013","author":"Mavrogiannaki A.N.","year":"2013","unstructured":"Mavrogiannaki A.N.; Migdalis I.N.; Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: Newer data. Int J Endocrinol 2013,2013,450639","journal-title":"Int J Endocrinol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00125-020-05253-x","volume":"63","author":"Yuan S.","year":"2020","unstructured":"Yuan S.; Larsson S.C.; An atlas on risk factors for type 2 diabetes: A wide-angled Mendelian randomisation study. Diabetologia 2020,63(11),2359-2371","journal-title":"Diabetologia"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2174\/1570161117666190502103733","volume":"18","author":"Faselis C.","year":"2020","unstructured":"Faselis C.; Katsimardou A.; Imprialos K.; Deligkaris P.; Kallistratos M.; Dimitriadis K.; Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol 2020,18(2),117-124","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40200-014-0084-3","volume":"13","author":"Parvizi M.R.","year":"2014","unstructured":"Parvizi M.R.; Parviz M.; Tavangar S.M.; Protective effect of magnesium on renal function in STZ-induced diabetic rats. J Diabetes Metab Disord 2014,13(1),84","journal-title":"J Diabetes Metab Disord"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1194\/jlr.P040501","volume":"55","author":"Herman-Edelstein M.","year":"2014","unstructured":"Herman-Edelstein M.; Scherzer P.; Tobar A.; Levi M.; Gafter U.; Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res 2014,55(3),561-572","journal-title":"J Lipid Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jab.2015.08.001","volume":"14","author":"Malekinejad H.","year":"2016","unstructured":"Malekinejad H.; Alizadeh-Fanalou S.; Hobbenaghi R.; Rokhsartalb-Azar S.; Atorvastatin up-regulates the expression and activity of renal cytochrome P450 3A2 in diabetic rats. J Appl Biomed 2016,14(1),25-34","journal-title":"J Appl Biomed"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1681\/ASN.2017060627","volume":"29","author":"Kim Y.","year":"2018","unstructured":"Kim Y.; Lim J.H.; Kim M.Y.; The adiponectin receptor agonist adiporon ameliorates diabetic nephropathy in a model of type 2 diabetes. J Am Soc Nephrol 2018,29(4),1108-1127","journal-title":"J Am Soc Nephrol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fphys.2018.00343","volume":"9","author":"Liu P.","year":"2018","unstructured":"Liu P.; Peng L.; Zhang H.; Tangshen formula attenuates diabetic nephropathy by promoting ABCA1-mediated renal cholesterol efflux in db\/db Mice. Front Physiol 2018,9,343","journal-title":"Front Physiol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3803\/EnM.2019.34.3.226","volume":"34","author":"Rhee E.J.","year":"2019","unstructured":"Rhee E.J.; Nonalcoholic fatty liver disease and diabetes: An epidemiological perspective. Endocrinol Metab (Seoul) 2019,34(3),226-233","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1194\/jlr.M017079","volume":"53","author":"Ji A.","year":"2012","unstructured":"Ji A.; Wroblewski J.M.; Cai L.; de Beer M.C.; Webb N.R.; van der Westhuyzen D.R.; Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. J Lipid Res 2012,53(3),446-455","journal-title":"J Lipid Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"17321","DOI":"10.1073\/pnas.1008499107","volume":"107","author":"Horie T.","year":"2010","unstructured":"Horie T.; Ono K.; Horiguchi M.; MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci 2010,107(40),17321-17326","journal-title":"Proc Natl Acad Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.117.032636","volume":"138","author":"Westerterp M.","year":"2018","unstructured":"Westerterp M.; Fotakis P.; Ouimet M.; Cholesterol efflux pathways suppress inflammasome activation, netosis, and atherogenesis. Circulation 2018,138(9),898-912","journal-title":"Circulation"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature10486","volume":"478","author":"Rayner K.J.","year":"2011","unstructured":"Rayner K.J.; Esau C.C.; Hussain F.N.; Inhibition of miR-33a\/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011,478(7369),404-407","journal-title":"Nature"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"9232","DOI":"10.1073\/pnas.1102281108","volume":"108","author":"D\u00e1valos A.","year":"2011","unstructured":"D\u00e1valos A.; Goedeke L.; Smibert P.; miR-33a\/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci 2011,108(22),9232-9237","journal-title":"Proc Natl Acad Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/s00125-010-1691-2","volume":"53","author":"Kruit J.K.","year":"2010","unstructured":"Kruit J.K.; Kremer P.H.; Dai L.; Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 2010,53(6),1110-1119","journal-title":"Diabetologia"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1194\/jlr.M003525","volume":"51","author":"Tang C.","year":"2010","unstructured":"Tang C.; Kanter J.E.; Bornfeldt K.E.; Leboeuf R.C.; Oram J.F.; Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J Lipid Res 2010,51(7),1719-1728","journal-title":"J Lipid Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1194\/jlr.M085886","volume":"59","author":"Lyu J.","year":"2018","unstructured":"Lyu J.; Imachi H.; Fukunaga K.; Angiotensin II induces cholesterol accumulation and impairs insulin secretion by regulating ABCA1 in beta cells. J Lipid Res 2018,59(10),1906-1915","journal-title":"J Lipid Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1080\/17474124.2016.1207523","volume":"10","author":"Ahmadian E.","year":"2016","unstructured":"Ahmadian E.; Pennefather P.S.; Eftekhari A.; Heidari R.; Eghbal M.A.; Role of renin-angiotensin system in liver diseases: An outline on the potential therapeutic points of intervention. Expert Rev Gastroenterol Hepatol 2016,10(11),1279-1288","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/13813455.2019.1647249","volume":"127","author":"Al-Hashem F.","year":"2021","unstructured":"Al-Hashem F.; Al Humayed S.; Haidara M.A.; Abdel Latif N.S.; Al-Ani B.; Captopril suppresses hepatic mammalian target of rapamycin cell signaling and biomarkers of inflammation and oxidative stress in thioacetamide-induced hepatotoxicity in rats. Arch Physiol Biochem 2021,127(5),414-421","journal-title":"Arch Physiol Biochem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1139\/apnm-2015-0145","volume":"40","author":"Abd Allah E.S.","year":"2015","unstructured":"Abd Allah E.S.; Gomaa A.M.; Effects of curcumin and captopril on the functions of kidney and nerve in streptozotocin-induced diabetic rats: Role of angiotensin converting enzyme 1. Appl Physiol Nutr Metab 2015,40(10),1061-1067","journal-title":"Appl Physiol Nutr Metab"},{"key":"ref=21","first-page":"3700","volume":"11","author":"Malika R.D.","year":"2019","unstructured":"Malika R.D.; Bahtiar A.; Captopril modulates behenic acid and L-hydroxyproline to lower blood glucose on high-fat diet and low-dose streptozotocin-induced diabetic-rats. J Pharm Sci Res 2019,11(12),3700-3704","journal-title":"J Pharm Sci Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jcph.1516","volume":"60","author":"Namdar H.","year":"2020","unstructured":"Namdar H.; Khani E.; Pourrashid M.H.; Entezari-Maleki T.; Effects of adding pentoxifylline to captopril on primary hypertension: A pilot randomized clinical trial. J Clin Pharmacol 2020,60(2),181-187","journal-title":"J Clin Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2017.01.029","volume":"97","author":"Zhang Y.","year":"2017","unstructured":"Zhang Y.; Li X.L.; Sha N.N.; Differential response of bone and kidney to ACEI in db\/db mice: A potential effect of captopril on accelerating bone loss. Bone 2017,97,222-232","journal-title":"Bone"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e12148","DOI":"10.5812\/numonthly.12148","volume":"6","author":"Makhlough A.","year":"2014","unstructured":"Makhlough A.; Kashi Z.; Akha O.; Zaboli E.; Yazdanicharati J.; Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan. Nephrourol Mon 2014,6(1),e12148","journal-title":"Nephrourol Mon"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1210\/en.2009-0869","volume":"151","author":"Wada T.","year":"2010","unstructured":"Wada T.; Kenmochi H.; Miyashita Y.; Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010,151(5),2040-2049","journal-title":"Endocrinology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1089\/dna.2019.4732","volume":"38","author":"Ebadi Z.","year":"2019","unstructured":"Ebadi Z.; Moradi N.; Kazemi Fard T.; Captopril and spironolactone can attenuate diabetic nephropathy in wistar rats by targeting microRNA-192 and microRNA-29a\/b\/c. DNA Cell Biol 2019,38(10),1134-1142","journal-title":"DNA Cell Biol"},{"key":"ref=27","first-page":"493","volume":"15","author":"Amniattalab A.","year":"2016","unstructured":"Amniattalab A.; Malekinejad H.; Rezabakhsh A.; Rokhsartalab-Azar S.; Alizade-Fanalou S.; Silymarin: A novel natural agent to restore defective pancreatic \u03b2 cells in streptozotocin (STZ)-induced diabetic rats. Iran J Pharm Res 2016,15(3),493-500","journal-title":"Iran J Pharm Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13510002.2020.1763714","volume":"25","author":"AlSaad A.M.S.","year":"2020","unstructured":"AlSaad A.M.S.; Alasmari F.; Abuohashish H.M.; Mohany M.; Ahmed M.M.; Al-Rejaie S.S.; Renin angiotensin system blockage by losartan neutralize hypercholesterolemia-induced inflammatory and oxidative injuries. Redox Rep 2020,25(1),51-58","journal-title":"Redox Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"E1232","DOI":"10.1152\/ajpendo.00134.2018","volume":"315","author":"Fukunaga K.","year":"2018","unstructured":"Fukunaga K.; Imachi H.; Lyu J.; IGF1 suppresses cholesterol accumulation in the liver of growth hormone-deficient mice via the activation of ABCA1. Am J Physiol Endocrinol Metab 2018,315(6),E1232-E1241","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.yjmcc.2017.05.001","volume":"112","author":"Ganda A.","year":"2017","unstructured":"Ganda A.; Yvan-Charvet L.; Zhang Y.; Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD. J Mol Cell Cardiol 2017,112,114-122","journal-title":"J Mol Cell Cardiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5551\/jat.14.133","volume":"14","author":"Nakaya K.","year":"2007","unstructured":"Nakaya K.; Ayaori M.; Hisada T.; Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma. J Atheroscler Thromb 2007,14(3),133-141","journal-title":"J Atheroscler Thromb"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/FJC.0b013e31824fc5e3","volume":"59","author":"Chen H.Y.","year":"2012","unstructured":"Chen H.Y.; Xu Z.; Chen L.F.; Wang W.; Fang Q.; Yan X.W.; Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPAR\u03b3 activation. J Cardiovasc Pharmacol 2012,59(6),570-575","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220401143249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/202983\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220401143249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T16:46:37Z","timestamp":1691685997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/202983\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":32,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612828666220401143249","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}